Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 98%
filed 2026-08-31
Item 3.01
Microvast received written notice from Nasdaq on August 26, 2026, that the average closing bid price of its common stock fell below the $1 minimum required under Nasdaq Rule 5450(a)(1). The company has 180 days to cure the deficiency; failure to do so would trigger a delisting notice and potential removal from Nasdaq. This is a classic delisting-risk disclosure under Item 3.01(a) of Form 8-K, materially affecting investor assessment of the registrant's continued public listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-08-31
EX-99.1
The exhibit discloses that Zentek's common shares are ceasing to trade on the Nasdaq Capital Market and transitioning to OTC Markets quotation effective September 2, 2026. While framed as a correction to a prior release, the substance is a material delisting from Nasdaq to OTC tier status, which materially affects trading liquidity and investor access. The company notes it has applied for OTCQX Best Market admission but until approved will trade on an initial OTC tier, and acknowledges that "trading in the common shares over the counter in the United States may be less liquid than trading on a national securities exchange."
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-31
Item 3.01
The filing discloses that Nasdaq's Listing and Hearing Review Council affirmed a decision to delist Cambium Networks' ordinary shares from Nasdaq based on non-compliance with Listing Rule 5250(c)(1), with trading suspended since March 27, 2026. This is a definitive delisting determination (not merely a risk or warning), making it a material event that directly affects the registrant's market access and investor base. The company expects shares to trade on OTC Markets, but the loss of Nasdaq listing is a terminal market event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-31
Item 3.01
Profusa received a Determination Letter from Nasdaq on August 26, 2026, notifying the Company that following its 1-for-4 reverse stock split, it had fewer than the 500,000 publicly held shares required under Nasdaq Listing Rule 5550(a)(4). Although Nasdaq subsequently determined compliance as of August 21, 2026, the filing itself discloses receipt of a deficiency notification under Item 3.01 and explicitly states this is filed to comply with Nasdaq Listing Rule 5810(b) requiring prompt disclosure of such notices. This is a material delisting-risk disclosure even though the immediate compliance issue was resolved.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-31
Item 3.03
Change Agents Corporation implemented a 1-for-20 reverse stock split effective August 28, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. The reverse split, approved by stockholders on June 9, 2026, and effectuated via Charter Amendment, directly addresses the company's delisting risk stemming from its stock price falling below the Nasdaq listing threshold.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-31
MicroVision received written notice from Nasdaq Listing Qualifications on August 26, 2026, confirming that it had regained compliance with Listing Rule 5550(a)(2) (minimum bid price of $1 per share) and that the matter is now closed. The company had previously been notified of noncompliance on January 12, 2026. This disclosure directly addresses delisting risk—the resolution of a prior listing compliance failure—and is material to investors as it removes the threat of delisting from Nasdaq.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-31
EX-99.1
The exhibit announces that TryHard has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) after previously failing to maintain the $1.00 minimum on March 11, 2026. The company executed a 10-for-1 reverse stock split approved on July 6, 2026, and achieved compliance by August 28, 2026. This disclosure directly addresses delisting risk—the resolution of a continued listing deficiency that threatened the company's Nasdaq listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-31
DNA X received notice from Nasdaq's Hearings Panel on August 28, 2026 that while the Company has regained compliance with the stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)), its securities remain subject to delisting if compliance is not maintained until November 18, 2026. Additionally, the Company is subject to a mandatory panel monitor through August 28, 2027, with the explicit warning that any future non-compliance will result in immediate delisting determination without opportunity for a compliance plan or cure period. This is a material delisting risk disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-31
Item 3.01
NYSE Regulation commenced delisting proceedings against Northann Corp.'s common stock from NYSE American LLC, with written notification received on August 21, 2026. The Company requested an oral hearing before the Listings Qualifications Panel on August 28, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-31
Item 3.01
Flag Ship Acquisition Corp received notice from Nasdaq on August 28, 2026 approving a voluntary transfer of its Securities' listing from The Nasdaq Global Market to The Nasdaq Capital Market. The filing explicitly states the transfer was made "to facilitate its compliance with the applicable Nasdaq listing standards," indicating the company faced compliance issues that necessitated the downgrade. While characterized as voluntary, this transfer represents a material change in listing status that would affect investor assessment of the registrant's standing and market tier.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Socket Mobile received a Notice from Nasdaq on August 24, 2026, stating it no longer complies with Nasdaq Listing Rule 5550(b)(1) requiring minimum stockholders' equity of $2.5 million; the Company reported only $2,382,624 in stockholders' equity as of June 30, 2026. The Company has 45 calendar days to submit a compliance plan and faces potential delisting if it cannot regain compliance. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-28
EX-99.1
Zentek received notice from Nasdaq that its common shares will be delisted from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement, effective September 2, 2026. The company's shares will transition to OTC Markets Group trading. This is a material delisting event that directly affects the registrant's listing status and market accessibility, even though the primary listing on TSX Venture Exchange remains unaffected.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-08-28
EX-99.1
The press release announces XORTX's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. While framed as a cost-reduction measure, a delisting materially affects the registrant's listing status and investor access to trading venues. The disclosure also includes a corrective disclosure of US$240,000 in finder's fees related to the Vectus acquisition that were inadvertently omitted from the April 2026 announcement, which is a material accounting correction. The primary event is the delisting announcement.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
Item 3.01
Gulf Resources received a notice from Nasdaq on August 24, 2026 indicating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Q2 2026 Form 10-Q. The company is required to submit a compliance plan and remains delinquent on multiple periodic filings (Q1 and Q2 2026 10-Qs). This is a classic delisting-risk disclosure under Item 3.01, as the company faces potential delisting if it fails to regain compliance with Nasdaq's continued listing standards.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
Item 8.01
The filing discloses that Nasdaq's Staff determined the Company should be delisted, trading was suspended on August 26, 2026, and the Company has scheduled a hearing before the Nasdaq Hearings Panel on September 29, 2026 to appeal the delisting determination and request continued listing. The Company explicitly acknowledges "there can be no assurance that the Panel will grant the Company's request for continued listing," indicating material delisting risk under Item 8.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
Item 3.01
Azio AI Holdings received a formal notice from Nasdaq on August 28, 2026, for failure to comply with Nasdaq Listing Rule 5635(b) regarding shareholder approval for securities issuances resulting in a change of control. Although Nasdaq determined the deficiency was remediated through removal of four officers effective August 27, 2026, and the matter is now closed with no immediate delisting effect, the notice constitutes a material disclosure of a listing rule violation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Item 3.01
GeoVax Labs received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company of a decision to delist its common stock due to failure to maintain the minimum $1.00 per share bid price for 30 consecutive business days and non-compliance with the $2,500,000 stockholders' equity requirement. Trading suspension is expected September 8, 2026 absent a timely hearing request. This is a direct delisting notice under Item 3.01, representing a material threat to the company's continued public listing and market access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Netcapital received a delinquency notification from Nasdaq on August 24, 2026 for failure to timely file its Form 10-K for fiscal year ended April 30, 2026, placing it in violation of Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan and faces potential delisting if it cannot regain compliance. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-28
The filing discloses a 1-for-8 reverse stock split implemented on August 28, 2026, explicitly stated to be "intended to, among other things, assist the Company in maintaining compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market." This language signals that the company faced delisting risk due to failure to meet Nasdaq's minimum bid price rule, making the reverse split a remedial action to preserve listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
Item 3.01 discloses that Nasdaq has determined to delist Jupiter Neurosciences' common stock from The Nasdaq Capital Market because the market value of listed securities fell below the $35 million minimum required under Listing Rule 5550(b)(2) for 30 consecutive trading days, and the Company failed to regain compliance within the 180-day cure period ending August 25, 2026. While the Company intends to appeal, the delisting determination is final and material to investors.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
My Size, Inc. received a notice from Nasdaq on August 25, 2026 that its stockholders' equity of $2,347,000 as of June 30, 2026 falls below the minimum $2,500,000 requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within any extension period granted. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Shuttle Pharmaceuticals received a notification letter from Nasdaq on August 28, 2026, indicating noncompliance with Nasdaq Listing Rule 5250(c)(1) due to delayed filing of its Form 10-Q for the period ended June 30, 2026. The company has 60 days to submit a compliance plan and up to 180 days to regain compliance, with explicit warning that failure to do so will result in delisting from Nasdaq. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
On August 26, 2026, Oragenics received a deficiency notice from NYSE American stating the company is not in compliance with continued listing standards (Sections 1003(a)(ii) and 1003(a)(iii)) due to stockholders' equity of $3.7 million falling below the $6 million threshold required for companies with net losses in five consecutive fiscal years. The company has until February 25, 2028 to regain compliance or face delisting procedures, with the stock now trading under the ".BC" (below compliance) designation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
AiRWA Inc. received a deficiency notification from Nasdaq on August 24, 2026, for failure to timely file its Annual Report on Form 10-K, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan and up to 180 days to regain compliance, with no assurance of success. This is a classic delisting-risk disclosure under Item 3.01, materially threatening the company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Item 3.01
The filing discloses that the Nasdaq Listing Council has affirmed a determination to delist BioAtla's common stock from Nasdaq effective August 31, 2026, due to non-compliance with the $1.00 bid price requirement and $2.5 million stockholders' equity requirement. The Company expects trading suspension on Nasdaq and transfer to OTC Markets, which the filing acknowledges "may have a material adverse effect on the trading price and volume for the Common Stock." This is a definitive delisting notice, not merely a risk or warning.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-28
EX-99.1
The exhibit discloses that Trinity Biotech received a Nasdaq staff determination letter on August 28, 2026, notifying the company that it failed to regain compliance with the market value of publicly held shares (MVPHS) requirement of $15 million by the August 18, 2026 deadline. The company's securities are now subject to suspension/delisting unless it requests and obtains a hearing before a Nasdaq Hearings Panel. This is a material delisting risk disclosure under Item 3.01 equivalent, as the company faces imminent delisting absent successful remediation or panel extension.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Item 3.01
KALA BIO received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its closing bid price has been below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a reverse stock split effected on May 11, 2026, and faces potential delisting unless it successfully appeals to the Nasdaq Hearings Panel. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-08-27
Natuzzi received written notice from NYSE on August 26, 2026, that the exchange has suspended trading and commenced delisting proceedings for the company's ADSs due to failure to maintain the required minimum average global market capitalization of $15 million over a consecutive 30 trading-day period. This is a direct notice of delisting risk and involuntary suspension, which materially affects the registrant's continued listing status and shareholder access to U.S. capital markets.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 99%
filed 2026-08-27
Item 3.01
Rein Therapeutics received a formal notice of delisting from Nasdaq on August 21, 2026, for failing to maintain the minimum bid price of $1.00 per share under Rule 5550(a)(1). The company has 180 days (until February 17, 2027) to regain compliance or face suspension and delisting procedures. This is a direct and material delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-27
The filing discloses that Onfolio Holdings received notice from Nasdaq on July 2, 2026, that its common stock failed to maintain the minimum bid price of $1.00 required by Listing Rule 5550(a)(2). Although the company subsequently regained compliance by August 25, 2026, the core event is the delisting risk notice and the company's efforts to cure the deficiency. Item 3.01 explicitly addresses "Notice of Delisting or Failure to Satisfy a Continued Listing Rule," and the filing documents the company's prior non-compliance and subsequent remediation through a reverse split.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-27
Item 3.01
Bleichroeder Acquisition Corp. II notified Nasdaq of the consummation of its business combination and requested suspension of trading in its units, Class A ordinary shares, and redeemable warrants, with planned filing of Form 25 for delisting and Form 15 for deregistration under the Exchange Act. This is an orderly delisting of Bleichroeder's securities in connection with the SPAC merger completion, with Pasqal's new Nasdaq listing replacing it.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-27
Item 3.01
SOBR Safe received a second Nasdaq staff determination letter on August 21, 2026, notifying the company that its stockholders' equity fell below the $2.5 million minimum requirement under Nasdaq Listing Rule 5550(b)(1). The company has until September 15, 2026 to regain compliance or complete a business combination, or face delisting from the Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-08-27
Glucotrack announced a 1-for-15 reverse stock split effective August 31, 2026, explicitly to "bring Glucotrack into compliance with the $1.00 minimum bid price requirement for maintaining the listing of its Common Stock on the Nasdaq Capital Market." The filing discloses that the company must maintain a $1.00 closing bid price through November 9, 2026, and warns that "if the Company fails to maintain compliance with Nasdaq listing requirements prior to November 9, 2026, its securities may be delisted at Nasdaq's discretion." This is a material delisting-risk disclosure tied to a compliance deadline.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-27
The filing discloses a notice from Nasdaq's Listing Qualifications Department (Item 3.01) that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to delinquent periodic filings (Form 10-Q for quarters ended March 31, 2026 and June 30, 2026). The Company has until October 12, 2026 to regain compliance, with a compliance plan due by September 4, 2026. This is a material delisting risk event that would substantially affect a reasonable investor's assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 90%
filed 2026-08-27
Item 3.03
Valion Bio implemented a 1-for-25 reverse stock split effective August 31, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a non-compliance notice on March 19, 2026. The company has until September 15, 2026, to cure the deficiency or face potential delisting from the Nasdaq Capital Market.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-26
EX-99.1
The press release announces that the TSX Continued Listing Committee has lifted its remedial delisting review of Largo, resolving a delisting risk that was previously disclosed in October 2025. The core disclosure is the resolution of a delisting threat — the company is "no longer under delisting review" and shares will "continue to trade on the TSX." This is a material event affecting the registrant's continued listing status and investor confidence.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-26
Item 3.01
The filing discloses a delisting notice from Nasdaq on August 6, 2026, for failure to maintain the required $35 million market value of listed securities under Nasdaq Listing Rule 5550(b)(2). Although the company subsequently demonstrated compliance with the alternative stockholders' equity requirement ($83.8 million) and the matter was closed on August 25, 2026, the initial delisting notification and the company's temporary non-compliance with continued listing standards constitute a material disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-26
EX-99.2
Vision Marine announced a 1-for-10 reverse stock split to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The company acknowledged that there can be no assurance the reverse split will succeed in addressing the underlying delisting compliance threat.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-26
EX-99.3
Vision Marine's Board approved voluntary delisting of the Company's common shares from the TSX Venture Exchange, effective August 26, 2026, representing a transfer of listing as the company consolidates its public-market presence on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-26
Item 3.01
Atlantic American received a Nasdaq notice on August 20, 2026 stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for Q2 2026, Form 10-K for 2025, and Form 10-Q for Q1 2026. Although the notice has no immediate effect on listing, the company faces a compliance deadline of October 12, 2026 and must submit an updated plan by September 4, 2026 or risk delisting proceedings. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-26
The 6-K discloses a Nasdaq notice that Primech failed to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), with the stock trading below $1.00 for 30 consecutive business days. Although the Company has been granted a 180-day cure period (until February 22, 2027) and faces no immediate delisting, this is a material disclosure of delisting risk under Item 3.01 equivalent. The notice explicitly warns of potential delisting if compliance is not regained, making this a significant governance and listing-status event material to investors.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-26
Item 1.01
Jasper Therapeutics received a notice from Nasdaq on August 21, 2026, that it no longer satisfies the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within an extended period. This is a direct delisting risk disclosure under Item 1.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 75%
filed 2026-08-26
Item 5.03
Future FinTech Group Inc. approved and effectuated a 1-for-4 reverse stock split, effective August 28, 2026, explicitly to address delisting risk by raising the stock price to at or above $1.00 per share to maintain compliance with Nasdaq's minimum bid price requirement. The company disclosed that failure to maintain compliance could result in non-compliance with Nasdaq continued listing standards or delisting proceedings.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-26
Item 7.01
The filing discloses that Flash Sports' common stock has been suspended from Nasdaq trading due to a Nasdaq Rules violation stemming from an administrative sequencing error in the listing process. The company has appealed to a Nasdaq Hearings Panel but notes "there can be no assurance regarding the timing or outcome of the appeal or the Company's ability to regain its Nasdaq listing." This is a material delisting risk event—the stock is currently trading on the OTC market following suspension, and the company faces uncertainty about restoring its Nasdaq listing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-26
EX-99.1
KNOREX received a notice from NYSE American on August 21, 2026, stating non-compliance with continued listing standards under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. The Company reported a stockholders' deficit of $6.5 million as of December 31, 2025, and net losses in four consecutive fiscal years, triggering the requirement for minimum stockholders' equity of $4.0 million. The Company has until February 21, 2028, to regain compliance or face delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-26
Item 3.01
CaliberCos received formal notice from Nasdaq on August 21, 2026, that its Class A common stock failed to meet the Minimum Bid Requirement (Nasdaq Listing Rule 5550(a)(2)) after closing below $1.00 per share for 33 consecutive business days. The company has been afforded a 180-calendar day grace period through February 17, 2027, to regain compliance. This is a classic delisting-risk disclosure under Item 3.01, with explicit acknowledgment that failure to cure could result in delisting and trading on OTC Markets.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-26
Item 3.01
Kraft Heinz announced a voluntary transfer of its common stock listing from Nasdaq to the New York Stock Exchange, effective September 14, 2026. This is a strategic, planned transition to a major exchange rather than a delisting due to non-compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-26
Item 3.01
Nasdaq notified American Resources Corporation on August 20, 2026 of non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its June 30, 2026 Form 10-Q. This is a classic delisting-risk disclosure under Item 3.01: the company has received formal notice of a continued listing rule violation and must submit a compliance plan by September 4, 2026 to avoid potential delisting. The company faces a deadline of October 15, 2026 to cure the delinquency, with the added complication that a prior March 10-Q filing remains outstanding.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-08-25
EX-99.1
The exhibit announces New Found Gold's graduation from the TSX Venture Exchange to the Toronto Stock Exchange, with trading commencing August 26, 2026 under symbol "NFGC." The company will be "voluntarily delisted from the TSX Venture Exchange upon the commencement of trading on the TSX." While this is a positive corporate milestone reflecting the company's advancement to an emerging producer, the delisting from TSX-V and transfer of listing to TSX is a material change in listing status that affects investor access and trading venue, warranting classification under delisting_risk (Item 3.01 equivalent) as a listing transfer event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-25
Item 3.01
The filing discloses that Datavault AI Inc. failed to regain compliance with Nasdaq's Minimum Bid Price Requirement ($1.00 per share) by the initial August 24, 2026 deadline, but has been granted a second 180-day compliance period until February 22, 2027. The company's stock remains listed but faces delisting if it cannot achieve the minimum bid price during the extended period. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued exchange listing status.
View raw filing on EDGAR →